Market News

Stay updated with the latest market trends, earnings, and economic indicators.

Showing news for:MOCAPITALHealthcare
Clear all filters
Market Trading Guide: ONGC among 2 stocks to buy on Friday for up to 16% returns
neutral
ET Markets - Stocks 142d ago

Market Trading Guide: ONGC among 2 stocks to buy on Friday for up to 16% returns

Nifty ended sharply lower as US-Iran tensions sparked a broad sell-off, breaking its three-day gain streak. Stock picks include ONGC and Biocon, showing strong bullish momentum on short-term charts. Traders are advised to follow breakout levels with prudent stop-losses.

AONETMMQ50AONETOTALBIOCONGROWWMOM50LTGILTBEESMIDSMALLMOCAPITALMOM30IETFMOMENTUMMOMENTUM30MOMENTUM50MOMIDMTMMOMOMENTUMONGCPRUDENTSMALLCAPFinancial ServicesHealthcare
Trade Spotlight: How should you trade Torrent Power, Bajaj Auto, Hindustan Aeronautics, Sun Pharma, PFC, Aditya Birla Capital, and others on June 23?
positive
Moneycontrol NaNd ago

Trade Spotlight: How should you trade Torrent Power, Bajaj Auto, Hindustan Aeronautics, Sun Pharma, PFC, Aditya Birla Capital, and others on June 23?

The market trend remains healthy, but a sustained close above long-term moving averages is needed for further sharp upside. Below are some short-term trading ideas to consider.

ABCAPITALABFRLABGSECABLBLABRELABSL10BANKABSLAMCABSLBANETFABSLLIQUIDABSLNN50ETABSLPSEAKCAPITBAJAJ-AUTOBIRLACORPNBIRLAMONEYBSLGOLDETFBSLNIFTYBSLSENETFGCPCAPGSEC10ABSLGVPILHALHEALTHYLTGILTBEESMOCAPITALMOMENTUMNIFTYQLITYPFCSILVERSPARCTECHTORNTPOWERAutomobile and Auto ComponentsCapital Goods
Neutral Zydus LifeSciences; target of Rs 1080: Motilal Oswal
positive
Moneycontrol NaNd ago

Neutral Zydus LifeSciences; target of Rs 1080: Motilal Oswal

Motilal Oswal recommended Neutral rating on Zydus LifeSciences with a target price of Rs 1080 in its research report dated May 20, 2026.

MOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEZYDUSLIFEFinancial ServicesHealthcare
Biocon eyes in-licensing deals to accelerate biosimilars growth
positive
Moneycontrol NaNd ago

Biocon eyes in-licensing deals to accelerate biosimilars growth

Developing a biosimilar requires years of research and significant capital. In-licensing allows companies to acquire or partner on near-market or approved assets

AKCAPITBIOCONCPCAPMOCAPITALFinancial ServicesHealthcare
Neutral Blue Star; target of Rs 1920: Motilal Oswal
positive
Moneycontrol NaNd ago

Neutral Blue Star; target of Rs 1920: Motilal Oswal

Motilal Oswal recommended Neutral rating on Blue Star with a target price of Rs 1920 in its research report dated May 07, 2026.

BLUESTARCOMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUESTARConsumer DurablesFinancial Services
Neutral Lupin; target of Rs 2520: Motilal Oswal
positive
Moneycontrol NaNd ago

Neutral Lupin; target of Rs 2520: Motilal Oswal

Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 2520 in its research report dated May 10, 2026.

LUPINMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEFinancial ServicesHealthcare
Buy Ajanta Pharma; target of Rs 3400: Motilal Oswal
positive
Moneycontrol NaNd ago

Buy Ajanta Pharma; target of Rs 3400: Motilal Oswal

Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3400 in its research report dated May 05, 2026.

AJANTPHARMMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUESPARCFinancial ServicesHealthcare
SBI MF, Nippon India MF buy Rs 272 crore worth Pine Labs shares; ICICI Pru MF acquire 1.5% stake in Indoco Remedies
positive
Moneycontrol NaNd ago

SBI MF, Nippon India MF buy Rs 272 crore worth Pine Labs shares; ICICI Pru MF acquire 1.5% stake in Indoco Remedies

SBI Mutual Fund through SBI Midcap Fund held 5.24 percent stake in Pine Labs, the point of sale and payment systems provider, as of March 2026.

ABSLPSEALPHAALPHAETFAONEGOLDAONELIQUIDAONENIFTYAONESILVERAONETOTALAUTOBEESAUTOIETFAXISBPSETFBANK10ADDBANKADDBANKBETFBANKETFBANKPSUBBETF0432BBNPNBETFBBNPPGOLDBFSIBNKETFAXISCHEMICALCHOICEGOLDCOMMOIETFCONSUMAXISDEFENCEDIVIDENDEBANKNIFTYEBBETF0430EBBETF0431EBBETF0433ECAPINSUREEGOLDELIQUIDELM250ENERGYENIFTYEQUAL200EQUAL50EQUAL50ADDESENSEXESGESILVERFINIETFFLEXIADDFMCGADDFMCGIETFGILT10BETAGILT5BETAGOLD1GOLD360GOLDADDGOLDAXISGOLDBETAGOLDBNDGOLDETFGROWWCAPMGROWWCHEMGROWWDEFNCGROWWEVGROWWGOLDGROWWHOSPIGROWWLIQIDGROWWLOVOLGROWWMC150GROWWMETALGROWWMOM50GROWWN200GROWWNETGROWWNIFTYGROWWNXT50GROWWPOWERGROWWPSEGROWWPSUBKGROWWRAILGROWWRLTYGROWWSC250GROWWSLVRGSEC10IETFGSEC10YEARHDFCGOLDHDFCGROWTHHDFCLOWVOLHDFCMID150HDFCMOMENTHDFCNEXT50HDFCNIF100HDFCNIFITHDFCPSUBKHDFCPVTBANHDFCQUALHDFCSILVERHDFCSML250HDFCVALUEHEALTHADDHEALTHAXISHEALTHCAREHEALTHIETFHSBCGOLDICICIB22INDOCOINFRAIETFINTERNETITADDITAXISITBEESITBETAITETFITIETFLICNETFSENLICNMID100LIQGRWBEESLIQUIDLIQUID1LIQUIDPLUSLIQUIDSBILIQUIDSHRILOWVOLMAFANGMAHKTECHMAKEINDIAMANUFGBEESMASPTOP50METALMETALIETFMID150MID150BEESMID150CASEMIDCAPMIDCAPADDMIDCAPBETAMIDCAPETFMIDCAPIETFMIDQ50ADDMIDSELIETFMNCMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM30IETFMOM50MOMENTUMMOMENTUM30MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTOURMOVALUEMSCIADDMSCIINDIAMULTICAPNEXT30ADDNEXT50NEXT50ADDNEXT50BETANEXT50ETFNEXT50IETFNIFTY100EWNIFTYADDNIFTYAXISNIFTYBETFNIFTYETFNIFTYQLITYOILIETFPHARMABEESPINELABSPSUBANKADDPSUBNKIETFPVTBANKADDQUALITY30RSYSTEMSSBIBPBSBICARDSBIETFCONSBIETFITSBIETFPBSBIETFQLTYSBILIQETFSBINEQWETFSBINMID150SBISILVERSDL26BEESSELECTIPOSENSEXAXISSENSEXETFSETF10GILTSILVERSILVER1SILVER360SILVERADDSILVERAGSILVERAXISSILVERBEESSILVERBETASILVERBNDSILVERIETFSMALL250SMALLADDSNXT30BEESTATAGOLDTATSILVTECHTNIDETFTOP10ADDTOP20TWCGOLDETFUNIONGOLDVAL30IETFVALUEVALUEAXISFinancial ServicesHealthcare
Neutral ALKEM Laboratories; target of Rs 5840: Motilal Oswal
positive
Moneycontrol NaNd ago

Neutral ALKEM Laboratories; target of Rs 5840: Motilal Oswal

Motilal Oswal recommended Neutral rating on ALKEM Laboratories with a target price of Rs 5840 in its research report dated May 28, 2026.

ALKEMMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEFinancial ServicesHealthcare
Buy Rubicon Research; target of Rs 1160: Motilal Oswal
positive
Moneycontrol NaNd ago

Buy Rubicon Research; target of Rs 1160: Motilal Oswal

Motilal Oswal is bullish on Rubicon Research recommended buy rating on the stock with a target price of Rs 1160 in its research report dated May 30, 2026.

MOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUERUBICONFinancial ServicesHealthcare
Buy Laurus Labs; target of Rs 1370: Motilal Oswal
positive
Moneycontrol NaNd ago

Buy Laurus Labs; target of Rs 1370: Motilal Oswal

Motilal Oswal is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 1370 in its research report dated April 30, 2026.

LAURUSLABSMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEFinancial ServicesHealthcare
Buy Ipca Laboratories; target of Rs 1730: Motilal Oswal
positive
Moneycontrol NaNd ago

Buy Ipca Laboratories; target of Rs 1730: Motilal Oswal

Motilal Oswal is bullish on Ipca Laboratories recommended buy rating on the stock with a target price of Rs 1730 in its research report dated June 01, 2026.

IPCALABMOALPHA50MOBANK10MOCAPITALMODEFENCEMOENERGYMOGOLDMOGSECMOHEALTHMOINFRAMOIPOMOLOWVOLMOM100MOM50MOMENTUM50MOMGFMOMIDMTMMOMNCMOMOMENTUMMON100MON50EQUALMONEXT50MONIFTY100MONIFTY500MONQ50MOPSEMOQUALITYMOREALTYMOSERVICEMOSILVERMOSMALL250MOTILALOFSMOTOURMOVALUEFinancial ServicesHealthcare